Ftse Mib
35.398,82
0,00%
DAX
18.707,28
0,00%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.626,51
0,70%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Matinas Biopharma Holdings Inc (MTNB) Matinas Biopharma Holdings Inc (MTNB) Notizie

MTNB

Matinas Biopharma (MTNB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:MTNB
DataOraFonteTitoloSimboloCompagnia
16/05/202413:00GlobeNewswire Inc.New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024AMEX:MTNBMatinas Biopharma Holdings Inc
09/05/202422:06Edgar (US Regulatory)Form 8-K - Current reportAMEX:MTNBMatinas Biopharma Holdings Inc
09/05/202422:05GlobeNewswire Inc.Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
09/05/202422:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:MTNBMatinas Biopharma Holdings Inc
07/05/202414:00GlobeNewswire Inc.Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual MeetingAMEX:MTNBMatinas Biopharma Holdings Inc
02/05/202413:00GlobeNewswire Inc.Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024AMEX:MTNBMatinas Biopharma Holdings Inc
30/04/202414:00GlobeNewswire Inc.In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and ChemotherapyAMEX:MTNBMatinas Biopharma Holdings Inc
03/04/202414:30GlobeNewswire Inc.Matinas BioPharma Prices $10 Million Registered Direct OfferingAMEX:MTNBMatinas Biopharma Holdings Inc
27/03/202421:05GlobeNewswire Inc.Matinas BioPharma Reports 2023 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
25/03/202413:00GlobeNewswire Inc.Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel FormulationAMEX:MTNBMatinas Biopharma Holdings Inc
22/03/202414:15GlobeNewswire Inc.Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical ResponseAMEX:MTNBMatinas Biopharma Holdings Inc
22/03/202411:30GlobeNewswire Inc.Matinas BioPharma Regains Compliance with NYSE American Continued Listing StandardsAMEX:MTNBMatinas Biopharma Holdings Inc
26/02/202414:00GlobeNewswire Inc.Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical ResolutionAMEX:MTNBMatinas Biopharma Holdings Inc
20/02/202413:30GlobeNewswire Inc.Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive AspergillosisAMEX:MTNBMatinas Biopharma Holdings Inc
03/01/202413:00GlobeNewswire Inc.Matinas BioPharma to Present at Biotech Showcase 2024AMEX:MTNBMatinas Biopharma Holdings Inc
27/12/202313:30GlobeNewswire Inc.Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small OligonucleotidesAMEX:MTNBMatinas Biopharma Holdings Inc
21/12/202313:30GlobeNewswire Inc.Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAAMEX:MTNBMatinas Biopharma Holdings Inc
16/12/202303:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:MTNBMatinas Biopharma Holdings Inc
08/11/202322:05GlobeNewswire Inc.Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business UpdateAMEX:MTNBMatinas Biopharma Holdings Inc
07/11/202313:30GlobeNewswire Inc.Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma ModelAMEX:MTNBMatinas Biopharma Holdings Inc
01/11/202312:00GlobeNewswire Inc.Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023AMEX:MTNBMatinas Biopharma Holdings Inc
11/10/202316:25AllPennyStocks.comBiotech Catches Massive Premarket BidAMEX:MTNBMatinas Biopharma Holdings Inc
11/10/202313:30GlobeNewswire Inc.Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical ResolutionAMEX:MTNBMatinas Biopharma Holdings Inc
28/09/202313:00GlobeNewswire Inc.Matinas BioPharma to Present at Two Investment Conferences in October 2023AMEX:MTNBMatinas Biopharma Holdings Inc
27/09/202313:00GlobeNewswire Inc.Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeekAMEX:MTNBMatinas Biopharma Holdings Inc
22/09/202323:25GlobeNewswire Inc.Matinas BioPharma Announces Notification of NYSE American Continued Listing DeficiencyAMEX:MTNBMatinas Biopharma Holdings Inc
21/09/202315:35GlobeNewswire Inc.Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceAMEX:MTNBMatinas Biopharma Holdings Inc
19/09/202323:25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:MTNBMatinas Biopharma Holdings Inc
08/09/202323:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsAMEX:MTNBMatinas Biopharma Holdings Inc
06/09/202313:00GlobeNewswire Inc.Matinas BioPharma to Participate in the H.C. Wainwright Global Investment ConferenceAMEX:MTNBMatinas Biopharma Holdings Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:MTNB

La tua Cronologia

TSX
ZEB
BMO Equal Weight Banks I...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network